Winhycare Pharma · Research use only

GLP-1 Research Peptides (RUO)

GLP-1, GIP and glucagon receptor agonists studied in metabolic research. Winhycare Pharma supplies each of these peptides as research-grade material at >99% purity with QC documentation, for laboratory research use only.

Specification card for Amycretin research peptide: CAS 3005889-81-3, >99% purity, research use only

GLP-1 & Incretin Multi-Agonists: research peptides we supply

Amycretin research peptide

CAS 3005889-81-3 · ≈ 7846.58 g/mol

GLP-1 / amylin receptor co-agonist. Investigational; in clinical development and not yet approved by the US FDA, EMA or other major regulators for any indication.

Mazdutide research peptide

CAS 2259884-03-0 · 4563.14 g/mol

GLP-1 / glucagon dual receptor agonist. Approved as an active ingredient by China's NMPA (chronic weight management, 2025; glycaemic control in type 2 diabetes, 2025). Outside China it remains investigational and in late-stage clinical development, not yet approved by the US FDA or EMA.

Retatrutide research peptide

CAS 2381089-83-2 · 4731.33 g/mol · also supplied as API

GLP-1 / GIP / glucagon triple receptor agonist. Investigational; in clinical development (Phase 3) and not yet approved by the FDA, EMA or any regulator for any indication.

Semaglutide research peptide

CAS 910463-68-2 · 4113.58 g/mol · also supplied as API

GLP-1 receptor agonist (acylated 31-amino-acid peptide). Approved as an active ingredient by major regulators including the US FDA and EMA for type 2 diabetes and chronic weight management.

Survodutide research peptide

CAS 2805997-46-8 · 4231.69 g/mol

GLP-1 / glucagon dual receptor agonist. Investigational; in clinical development (Phase 3) and not yet approved by the FDA, EMA or other major regulators. It has received US FDA Breakthrough Therapy designation and EMA PRIME access in MASH, but its efficacy and safety have not been established for therapeutic use.

Tirzepatide research peptide

CAS 2023788-19-2 · 4813.53 g/mol · also supplied as API

GIP / GLP-1 dual receptor agonist. Approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and the EMA (2022 for type 2 diabetes).

PeptideCASMolecular weightSequencePurity
Amycretin3005889-81-3≈ 7846.58 g/mol68 amino acids (unimolecular GLP-1 and amylin receptor agonist moieties joined by a short Gly/Glu linker)>99%
Mazdutide2259884-03-04563.14 g/mol39 amino acids (oxyntomodulin analogue; Aib at position 2, acylated with a C20 di-acid side chain via AEEA-γGlu linker)>99%
Retatrutide2381089-83-24731.33 g/mol39 amino acids (acylated with a C20 fatty di-acid side chain at Lys17)>99%
Semaglutide910463-68-24113.58 g/mol31 amino acids (acylated with a C18 fatty di-acid side chain)>99%
Survodutide2805997-46-84231.69 g/mol29 amino acids (acylated with a C18 fatty di-acid side chain)>99%
Tirzepatide2023788-19-24813.53 g/mol39 amino acids (acylated with a C20 fatty di-acid side chain; C-terminal amide)>99%

Research use only. Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics. Buyers are responsible for complying with the import and use regulations of their country.

Frequently asked questions

Which glp-1 & incretin multi-agonists research peptides do you supply?

Amycretin, Mazdutide, Retatrutide, Semaglutide, Survodutide, Tirzepatide, each at >99% purity for research use only.

Are these peptides for human use?

No. They are supplied for laboratory research use only and are not for human or veterinary use. We do not provide dosing or usage advice.

What documentation comes with the material?

Material is supplied with QC documentation. Tell us in your enquiry what your lab or quality team needs.

Can I order bulk quantities?

Yes. Include the quantity in your enquiry; bulk and distributor quantities are quoted on request.

WhatsApp Us Get a Quote